Current status of the prognostic molecular biomarkers in breast cancer: A systematic review (Review)
- Authors:
- Goro Kutomi
- Toru Mizuguchi
- Fukino Satomi
- Hideki Maeda
- Hiroaki Shima
- Yasutoshi Kimura
- Koichi Hirata
-
Affiliations: Department of Surgery, Surgical Oncology and Science, Sapporo Medical University, Sapporo, Hokkaido 060‑8543, Japan - Published online on: January 17, 2017 https://doi.org/10.3892/ol.2017.5609
- Pages: 1491-1498
This article is mentioned in:
Abstract
 |
|
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B and Senn HJ: Panel members: Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol. 24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Henderson IC and Patek AJ: The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat. 52:261–288. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Lang JE, Wecsler JS, Press MF and Tripathy D: Molecular markers for breast cancer diagnosis, prognosis and targeted therapy. J Surg Oncol. 111:81–90. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 365:1687–1717. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Niederreither K and Dollé P: Retinoic acid in development: Towards an integrated view. Nat Rev Genet. 9:541–553. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hua S, Kittler R and White KP: Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell. 137:1259–1271. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Johansson HJ, Sanchez BC, Mundt F, Forshed J, Kovacs A, Panizza E, Hultin-Rosenberg L, Lundgren B, Martens U, Máthé G, et al: Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nat Commun. 4:21752013. View Article : Google Scholar : PubMed/NCBI | |
|
Esteban JM, Warsi Z, Haniu M, Hall P, Shively JE and Chen S: Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation. Am J Pathol. 140:337–343. 1992.PubMed/NCBI | |
|
Miki Y, Suzuki T and Sasano H: Controversies of aromatase localization in human breast cancer-stromal versus parenchymal cells. J Steroid Biochem Mol Biol. 106:97–101. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, Miller WR, Evans DB, Dugan M, Brady C, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol. 19:3808–3816. 2001.PubMed/NCBI | |
|
Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, et al: Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol. 12:1527–1532. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Ross HA Chaudri, von Kameke A, Miller WR, Smith I, et al: Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 100:1380–1388. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Ellis MJ, Coop A, Singh B, Tao Y, Llombart-Cussac A, Jänicke F, Mauriac L, Quebe-Fehling E, Chaudri-Ross HA, Evans DB and Miller WR: Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res. 63:6523–6531. 2003.PubMed/NCBI | |
|
Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 11:155–168. 1998.PubMed/NCBI | |
|
Ellis MJ, Miller WR, Tao Y, Evans DB, Ross HA Chaudri, Miki Y, Suzuki T and Sasano H: Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial. Breast Cancer Res Treat. 116:371–378. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Senger DR, Wirth DF and Hynes RO: Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell. 16:885–893. 1979. View Article : Google Scholar : PubMed/NCBI | |
|
Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF and Senger DR: Osteopontin expression and distribution in human carcinomas. Am J Pathol. 145:610–623. 1994.PubMed/NCBI | |
|
Pang H, Lu H, Song H, Meng Q, Zhao Y, Liu N, Lan F, Liu Y, Yan S, Dong X and Cai L: Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer. Cancer Epidemiol. 37:985–992. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ortiz-Martínez F, Perez-Balaguer A, Ciprián D, Andrés L, Ponce J, Adrover E, Sánchez-Payá J, Aranda FI, Lerma E and Peiró G: Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence. Hum Pathol. 45:504–512. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Bramwell VH, Tuck AB, Chapman JA, Anborgh PH, Postenka CO, Al-Katib W, Shepherd LE, Han L, Wilson CF, Pritchard KI, et al: Assessment of osteopontin in early breast cancer: Correlative study in a randomised clinical trial. Breast Cancer Res. 16:R82014. View Article : Google Scholar : PubMed/NCBI | |
|
Ohno S, Chow LW, Sato N, Masuda N, Sasano H, Takahashi F, Bando H, Iwata H, Morimoto T, Kamigaki S, et al: Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: Exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 142:69–80. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Denkert C, Loibl S, Muller BM, Eidtmann H, Schmitt WD, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, et al: Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: A translational investigation in the neoadjuvant GeparTrio trial. Ann Oncol. 24:2786–2793. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Budczies J, Klauschen F, Sinn BV, Győrffy B, Schmitt WD, Darb-Esfahani S and Denkert C: Cutoff finder: A comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS One. 7:e518622012. View Article : Google Scholar : PubMed/NCBI | |
|
DeCensi A, Guerrieri-Gonzaga A, Gandini S, Serrano D, Cazzaniga M, Mora S, Johansson H, Lien EA, Pruneri G, Viale G and Bonanni B: Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol. 22:582–587. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kuroki M, Matsuo Y, Kinugasa T and Matsuoka Y: Three different NCA species, CGM6/CD67, NCA-95 and NCA-90, are comprised in the major 90 to 100-kDa band of granulocyte NCA detectable upon SDS-polyacrylamide gel electrophoresis. Biochem Biophys Res Commun. 182:501–506. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Blumenthal RD, Leon E, Hansen HJ and Goldenberg DM: Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers. BMC cancer. 7:22007. View Article : Google Scholar : PubMed/NCBI | |
|
Poola I, Shokrani B, Bhatnagar R, DeWitty RL, Yue Q and Bonney G: Expression of carcinoembryonic antigen cell adhesion molecule 6 oncoprotein in atypical ductal hyperplastic tissues is associated with the development of invasive breast cancer. Clin Cancer Res. 12:4773–4783. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Tsang JY, Kwok YK, Chan KW, Ni YB, Chow WN, Lau KF, Shao MM, Chan SK, Tan PH and Tse GM: Expression and clinical significance of carcinoembryonic antigen-related cell adhesion molecule 6 in breast cancers. Breast Cancer Res Treat. 142:311–322. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
German S, Aslam HM, Saleem S, Raees A, Anum T, Alvi AA and Haseeb A: Carcinogenesis of PIK3CA. Hered Cancer Clin Pract. 11:52013. View Article : Google Scholar : PubMed/NCBI | |
|
Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, et al: Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc Natl Acad Sci USA. 110:14372–14377. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Cizkova M, Dujaric ME, Lehmann-Che J, Scott V, Tembo O, Asselain B, Pierga JY, Marty M, de Cremoux P, Spyratos F and Bieche I: Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab. Br J Cancer. 108:1807–1809. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Hortobagyi GN and Holmes FA: Single-agent paclitaxel for the treatment of breast cancer: An overview. Semin Oncol. 23(1): Suppl 1. S4–S9. 1996. | |
|
Bergh J, Jönsson PE, Glimelius B and Nygren P: SBU-group. Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol. 40:253–281. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Chromek M, Tullus K, Lundahl J and Brauner A: Tissue inhibitor of metalloproteinase 1 activates normal human granulocytes, protects them from apoptosis, and blocks their transmigration during inflammation. Infect Immun. 72:82–88. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Schrohl AS, Meijer-van Gelder ME, Holten-Andersen MN, Christensen IJ, Look MP, Mouridsen HT, Brünner N and Foekens JA: Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. Clin Cancer Res. 12:7054–7058. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu D, Zha X, Hu M, Tao A, Zhou H, Zhou X and Sun Y: High expression of TIMP-1 in human breast cancer tissues is a predictive of resistance to paclitaxel-based chemotherapy. Med Oncol. 29:3207–3215. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Arosio P, Yokota M and Drysdale JW: Structural and immunological relationships of isoferritins in normal and malignant cells. Cancer Res. 36:1735–1739. 1976.PubMed/NCBI | |
|
Levi S, Yewdall SJ, Harrison PM, Santambrogio P, Cozzi A, Rovida E, Albertini A and Arosio P: Evidence of H- and L-chains have co-operative roles in the iron-uptake mechanism of human ferritin. Biochem J. 288:591–596. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Ricolleau G, Charbonnel C, Lodé L, Loussouarn D, Joalland MP, Bogumil R, Jourdain S, Minvielle S, Campone M, Déporte-Fety R, et al: Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors. Proteomics. 6:1963–1975. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Jézéquel P, Campion L, Spyratos F, Loussouarn D, Campone M, Guérin-Charbonnel C, Joalland MP, André J, Descotes F, Grenot C, et al: Validation of tumor-associated macrophage ferritin light chain as a prognostic biomarker in node-negative breast cancer tumors: A multicentric 2004 national PHRC study. Int J Cancer. 131:426–437. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Duffy MJ: Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: From pilot to level 1 evidence studies. Clin Chem. 48:1194–1197. 2002.PubMed/NCBI | |
|
Mengele K, Napieralski R, Magdolen V, Reuning U, Gkazepis A, Sweep F, Brünner N, Foekens J, Harbeck N and Schmitt M: Characteristics of the level-of-evedence-1 disease forcast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn. 10:947–962. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CG, Lisboa BW, Lux MP, Beck T, et al: Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American society of clinical oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer. 49:1825–1835. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Favaro E, Amadori A and Indraccolo S: Cellular interactions in the vascular niche: Implications in the regulation of tumor dormancy. APMIS. 116:648–659. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Allin KH and Nordestgaard BG: Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci. 48:155–170. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Villaseñor A, Flatt SW, Marinac C, Natarajan L, Pierce JP and Patterson RE: Postdiagnosis C-reactive protein and breast cancer survivorship: Findings from the WHEL study. Cancer Epidemiol Biomarkers Prev. 23:189–199. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zody MC, Garber M, Adams DJ, Sharpe T, Harrow J, Lupski JR, Nicholson C, Searle SM, Wilming L, Young SK, et al: DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage. Nature. 440:1045–1049. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Watters AD, Going JJ, Cooke TG and Bartlett JM: Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat. 77:109–114. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Corzo C, Bellosillo B, Corominas JM, Salido M, Coll MD, Serrano S, Albanell J, Solé F and Tusquets I: Does polysomy of chromosome 17 have a role in ERBB2 and topoisomerase IIalpha expression? Gene, mRNA and protein expression: A comprehensive analysis. Tumor Biol. 28:221–228. 2007. View Article : Google Scholar | |
|
Earl HM, Hiller L, Dunn JA, Vallier AL, Bowden SJ, Jordan SD, Blows F, Munro A, Bathers S, Grieve R, et al: Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: Results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. Br J Cancer. 107:1257–1267. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Sias PE, Kotts CE, Vetterlein D, Shepard M and Wong WL: ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids. J Immunol Methods. 132:73–80. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J and Baselga J: Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res. 59:1196–1201. 1999.PubMed/NCBI | |
|
Tse C, Gauchez AS, Jacot W and Lamy PJ: HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer. Cancer Treat Rev. 38:133–142. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 353:1673–1684. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Moreno-Aspitia A, Hillman DW, Dyar SH, Tenner KS, Gralow J, Kaufman PA, Davidson NE, Lafky JM, Reinholz MM, Lingle WL, et al: Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: Results from north central cancer treatment group adjuvant trial N9831. Cancer. 119:2675–2682. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Tsukasaki K, Miller CW, Greenspun E, Eshaghian S, Kawabata H, Fujimoto T, Tomonaga M, Sawyers C, Said JW and Koeffler HP: Mutations in the mitotic check point gene, MAD1L1, in human cancers. Oncogene. 20:3301–3305. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Sun Q, Zhang X, Liu T, Liu X, Geng J, He X, Liu Y and Pang D: Increased expression of mitotic arrest deficient-like 1 (MAD1L1) is associated with poor prognosis and insensitive to Taxol treatment in breast cancer. Breast Cancer Res Treat. 140:323–330. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Baylin SB and Herman JG: DNA hypermethylation in tumorigenesis: Epigenetics joins genetics. Trends Genet. 16:168–174. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Jones PA: DNA methylation errors and cancer. Cancer Res. 56:2463–2467. 1996.PubMed/NCBI | |
|
Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 349:2042–2054. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Frühwald MC: DNA methylation patterns in cancer: Novel prognostic indicators? Am J Pharmacogenomics. 3:245–260. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Laird PW: The power and the promise of DNA methylation markers. Nat Rev Cancer. 3:253–266. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Maier S, Nimmrich I, Koenig T, Eppenberger-Castori S, Bohlmann I, Paradiso A, Spyratos F, Thomssen C, Mueller V, Nährig J, et al: DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients-Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group. Eur J Cancer. 43:1679–1686. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Martens JW, Nimmrich I, Koenig T, Look MP, Harbeck N, Model F, Kluth A, Bolt-de Vries J, Sieuwerts AM, Portengen H, et al: Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res. 65:4101–4117. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Widschwendter M, Siegmund KD, Müller HM, Fiegl H, Marth C, Müller-Holzner E, Jones PA and Laird PW: Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res. 64:3807–3813. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Hartmann O, Spyratos F, Harbeck N, Dietrich D, Fassbender A, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Lerebours F, Welzel K, et al: DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy. Clin Cancer Res. 15:315–323. 2009. View Article : Google Scholar : PubMed/NCBI |
